Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 13/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 13/20 | 0.36 |
| ▸ | RXRA | P19793 | 4/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | SDHB | P21912 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20138120 | 0.84 | NR1H2 (0.39) | NR1H2NR1H3RXRASYKPTGDR2 | |
| SCHEMBL20138206 | 0.81 | P2RX7 (0.38) | GRIN1GRIN2B | |
| SCHEMBL20137962 | 0.81 | MAPK1 (0.36) | MTOR | |
| SCHEMBL20138102 | 0.73 | SMN1; SMN2 (0.37) | MTOR | |
| SCHEMBL20138224 | 0.71 | NR1H2 (0.42) | NR1H2NR1H3RXRASYKSDHB | |
| SCHEMBL20138190 | 0.67 | SMN1; SMN2 (0.38) | MTOR | |
| SCHEMBL20138175 | 0.67 | MAPK1 (0.34) | — | |
| SCHEMBL20137911 | 0.66 | MTOR (0.38) | MTOR | |
| SCHEMBL20138254 | 0.65 | TSHR (0.42) | — | |
| SCHEMBL20138205 | 0.65 | TSHR (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | UCB BIOPHARMA SPRL (BE) | 2019-05-14 | — | — | US | disclosed |
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | UCB S.A. (BE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | TNF, NFKBIA, TNFRSF1A | NR1H2 592/4885NR1H3 1456/4885RXRA 182/4885 |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | TNF, TNFRSF1A, NFKBIA | NR1H2 1167/4885NR1H3 2021/4885RXRA 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.